S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:SLDB

Solid Biosciences Competitors

$8.83
-1.06 (-10.72 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.14
Now: $8.83
$10.28
50-Day Range
$6.04
MA: $7.35
$10.72
52-Week Range
$1.93
Now: $8.83
$11.58
Volume1.22 million shs
Average Volume1.29 million shs
Market Capitalization$533.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1

Competitors

Solid Biosciences (NASDAQ:SLDB) Vs. KYMR, BCRX, BLUE, VCEL, SRRK, and OCGN

Should you be buying SLDB stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Solid Biosciences, including Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), Vericel (VCEL), Scholar Rock (SRRK), and Ocugen (OCGN).

Solid Biosciences (NASDAQ:SLDB) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Institutional & Insider Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Solid Biosciences and Kymera Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences02202.50
Kymera Therapeutics02402.67

Solid Biosciences currently has a consensus price target of $7.1250, suggesting a potential downside of 19.31%. Kymera Therapeutics has a consensus price target of $50.3333, suggesting a potential upside of 9.75%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Solid Biosciences.

Valuation & Earnings

This table compares Solid Biosciences and Kymera Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-3.03
Kymera TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Solid Biosciences and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
Kymera TherapeuticsN/AN/AN/A

Summary

Kymera Therapeutics beats Solid Biosciences on 5 of the 7 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Institutional & Insider Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Solid Biosciences and BioCryst Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences02202.50
BioCryst Pharmaceuticals03802.73

Solid Biosciences currently has a consensus price target of $7.1250, suggesting a potential downside of 19.31%. BioCryst Pharmaceuticals has a consensus price target of $11.3750, suggesting a potential upside of 4.17%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Solid Biosciences.

Volatility and Risk

Solid Biosciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500.

Valuation & Earnings

This table compares Solid Biosciences and BioCryst Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-3.03
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62

BioCryst Pharmaceuticals has higher revenue and earnings than Solid Biosciences. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solid Biosciences and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Summary

BioCryst Pharmaceuticals beats Solid Biosciences on 9 of the 13 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Institutional & Insider Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Solid Biosciences and bluebird bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences02202.50
bluebird bio013402.24

Solid Biosciences currently has a consensus price target of $7.1250, suggesting a potential downside of 19.31%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 145.05%. Given bluebird bio's higher possible upside, analysts clearly believe bluebird bio is more favorable than Solid Biosciences.

Volatility and Risk

Solid Biosciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Valuation & Earnings

This table compares Solid Biosciences and bluebird bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-3.03
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95

Solid Biosciences has higher earnings, but lower revenue than bluebird bio. Solid Biosciences is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solid Biosciences and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
bluebird bio-256.84%-45.78%-35.14%

Summary

bluebird bio beats Solid Biosciences on 8 of the 13 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares Solid Biosciences and Vericel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-3.03
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50

Vericel has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solid Biosciences and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
Vericel0.12%0.13%0.10%

Volatility and Risk

Solid Biosciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Institutional & Insider Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Comparatively, 4.3% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Solid Biosciences and Vericel, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences02202.50
Vericel02602.75

Solid Biosciences currently has a consensus price target of $7.1250, suggesting a potential downside of 19.31%. Vericel has a consensus price target of $49.00, suggesting a potential upside of 21.26%. Given Vericel's stronger consensus rating and higher possible upside, analysts clearly believe Vericel is more favorable than Solid Biosciences.

Summary

Vericel beats Solid Biosciences on 11 of the 13 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Solid Biosciences and Scholar Rock's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-3.03
Scholar Rock$20.49 million83.07$-51,000,000.00($1.85)-27.35

Scholar Rock has higher revenue and earnings than Solid Biosciences. Scholar Rock is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solid Biosciences and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
Scholar Rock-365.84%-80.16%-41.33%

Risk & Volatility

Solid Biosciences has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Institutional and Insider Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 61.9% of Scholar Rock shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Comparatively, 24.6% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Solid Biosciences and Scholar Rock, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences02202.50
Scholar Rock00503.00

Solid Biosciences currently has a consensus price target of $7.1250, suggesting a potential downside of 19.31%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 21.74%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Solid Biosciences.

Summary

Scholar Rock beats Solid Biosciences on 9 of the 13 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Solid Biosciences and Ocugen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-3.03
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solid Biosciences and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
OcugenN/A-47.72%-30.78%

Risk & Volatility

Solid Biosciences has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500.

Institutional and Insider Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Solid Biosciences and Ocugen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences02202.50
Ocugen01302.75

Solid Biosciences currently has a consensus price target of $7.1250, suggesting a potential downside of 19.31%. Ocugen has a consensus price target of $4.80, suggesting a potential downside of 46.49%. Given Solid Biosciences' higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than Ocugen.

Summary

Ocugen beats Solid Biosciences on 7 of the 11 factors compared between the two stocks.


Solid Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.